Seeking Alpha

The FDA says it needs another four weeks to finish reviewing Mannkind's (MNKD +5.4%) new drug...

The FDA says it needs another four weeks to finish reviewing Mannkind's (MNKD +5.4%) new drug application for Afrezza, an inhaled-insulin product. Mannkind, which has no products on the market, had been expecting FDA approval tomorrow. (PR)
Comments (1)
  • concretebd
    , contributor
    Comments (2) | Send Message
     
    Thanks to the Blizzard
    28 Dec 2010, 10:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector